Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Summary
- Isomorphic Labs raised $5 billion in a Series C funding round to advance drug candidates to clinical trials.
- The round was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and existing backers including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
- The company utilizes an AI drug-design engine based on DeepMind's AlphaFold protein-folding model to explore chemistry areas for drug design.
- Isomorphic Labs reported positive preclinical results in oncology and immunology and has established deals with Eli Lilly, Novartis, and Johnson & Johnson.
- Funding follows a $2.1 billion Series B round in May and will support engine development and expansion into additional medicine types.
- This is the first fundraise since CEO Demis Hassabis transitioned to focus on drug discovery while assuming a chairman role at DeepMind.
- Hassabis and John Jumper won the Nobel Prize in chemistry for AlphaFold, which predicts protein 3D structures from genetic sequences.
- Isomorphic Labs did not disclose its new valuation, though Bloomberg reported a potential $50 billion valuation target earlier in the month.
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.
- Keywords
- AI,Biotech & Health,Fundraising,AI drug discovery,DeepMind,drug research,isomorphic labs